1. Home
  2. Directory
  3. Utah
  4. Roosevelt
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1154974657

TANYA SARAH BOREN FNP
Prescription History 1154974657
Nurse Practitioner - Family in Roosevelt, UT


Quality Rating: 66.09 out of 100 score

NPI Status: Active since July 23, 2019

Contact Information

250 W 300 N
ROOSEVELT, UT
ZIP 84066
Phone: (435) 722-4691

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for TANYA SARAH BOREN FNP, an active Family specialist practicing in Roosevelt, UT. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 110 documented patient claims. Among these therapy options, the most frequently utilized medication is Ceftriaxone, which accounts for 42 claims alone.

Medication Index

C
D
V
No matching medications currently found on file.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 281
UT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply139
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 68.0% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,291.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.76

State Avg Cost Per Claim

$39.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Clindamycin Hcl

Generic Formulation: Clindamycin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 138
UT State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.3
Peer Average Days Supply144
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $153.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.81

State Avg Cost Per Claim

$12.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.

Therapeutic Applications

Clindamycin is used to treat a wide variety of bacterial infections. It is an antibiotic that works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 181
UT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply155
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,543.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$174.76

State Avg Cost Per Claim

$972.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 166
UT State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply81
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,804.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.24

State Avg Cost Per Claim

$83.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like TANYA SARAH BOREN FNP provides transparency into local medical care patterns within Roosevelt, UT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.